U.S. flag An official website of the United States government
  1. Home
  2. Regulatory Information
  3. Search for FDA Guidance Documents
  4. Guidance for Industry: Suicidal Ideation and Behavior: Prospective Assessment of Occurrence in Clinical Trials
  1. Search for FDA Guidance Documents


Guidance for Industry: Suicidal Ideation and Behavior: Prospective Assessment of Occurrence in Clinical Trials August 2012


Not for implementation. Contains non-binding recommendations.

Issued by:
Guidance Issuing Office
Center for Drug Evaluation and Research

The purpose of this guidance is to assist sponsors in prospectively assessing the occurrence of  treatment-emergent suicidal ideation and behavior in clinical trials of drug and biological  products.2 The focus of this guidance is on clinical trials conducted under investigational new  drug applications, or trials that are intended for submission in a new drug application or a  biologics license application. Specifically, this guidance addresses the Food and Drug Administration’s (FDA’s) current thinking regarding the importance of assessment of suicidal  ideation and behavior in psychiatric and nonpsychiatric drug trials falling under the authority of  the FDA, and the general principles for how best to accomplish this assessment during drug  development. This guidance is not intended to give advice on how best to screen patients for  entry into clinical trials, even though instruments used for assessing patients during the conduct of trials can also be used for screening patients. Making decisions about which patients to enter  into a particular trial is a separate matter that is determined largely by the questions that the trial  is intended to address.

Submit Comments

Submit comments on this guidance document electronically via docket ID: FDA-2013-S-0610 - Specific Electronic Submissions Intended For FDA's Dockets Management Staff (i.e., Citizen Petitions, Draft Proposed Guidance Documents, Variances, and other administrative record submissions)

If unable to submit comments online, please mail written comments to:

Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852

All comments should be identified with the title of the guidance.

Back to Top